Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive content changes to the study details are visible in the screenshots.SummaryDifference0.1%

- Check40 days agoChange DetectedThis study was terminated early due to changes in melanoma treatment, with termination dated 2026-01-29. The recruitment status 'Active, not recruiting' was removed from the record.SummaryDifference0.5%

- Check47 days agoChange DetectedThe page now shows a glossary, adds a 'Last Update Submitted that Met QC Criteria' field, a 'No FEAR Act Data' indicator, and a 'Revision: v3.4.0' note. The previous 'Last Update Submitted that met QC Criteria' field, FEAR Act wording, and the older 'Revision: v3.3.4' version have been removed.SummaryDifference0.2%

- Check54 days agoChange DetectedThe label 'Last Update Posted (Estimated)' was changed to 'Last Update Posted'.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.